Profile data is unavailable for this security.
About the company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
- Revenue in USD (TTM)4.80m
- Net income in USD-8.49m
- Incorporated2011
- Employees17.00
- LocationLipocine Inc675 S Arapeen Dr Ste 202SALT LAKE CITY 84108-1295United StatesUSA
- Phone+1 (801) 994-7383
- Fax+1 (801) 994-7388
- Websitehttps://www.lipocine.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 23.76m | 8.00 | -- | 1.22 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Lisata Therapeutics Inc | 0.00 | -21.07m | 24.21m | 25.00 | -- | 0.6331 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 11.17m | -66.17m | 24.84m | 100.00 | -- | 0.2893 | -- | 2.22 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -7.51m | 25.12m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -113.45m | 25.37m | 65.00 | -- | 0.3044 | -- | -- | -2.97 | -2.97 | 0.00 | 2.17 | 0.00 | -- | -- | 0.00 | -71.06 | -30.73 | -83.81 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Palatin Technologies, Inc. | 4.49m | -29.74m | 25.41m | 30.00 | -- | -- | -- | 5.66 | -1.97 | -1.97 | 0.2981 | -0.0062 | 0.3131 | 0.3713 | 3.08 | 149,669.70 | -207.35 | -55.28 | -1,527.99 | -69.08 | 97.83 | -- | -662.26 | -1,359.14 | 1.01 | -- | -- | -- | -7.49 | -40.52 | -23.71 | -- | 3.31 | -- |
| Lipocine Inc | 4.80m | -8.49m | 25.46m | 17.00 | -- | 1.20 | -- | 5.30 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Cell Source Inc | 0.00 | -6.45m | 25.67m | -- | -- | -- | -- | -- | -0.1627 | -0.1627 | 0.00 | -0.413 | 0.00 | -- | -- | -- | -1,300.91 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -5.14 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 507.20k | -4.14m | 26.34m | 5.00 | -- | 1.84 | -- | 51.92 | -4.95 | -4.95 | 0.5919 | 1.79 | 0.1788 | -- | 16.01 | 101,440.00 | -146.02 | -- | -169.27 | -- | -- | -- | -816.72 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 26.55m | 4.00 | -- | 4.74 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 26.59m | 35.00 | -- | 1.33 | -- | 2,659.32 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| Estrella Immunopharma Inc | 0.00 | -7.31m | 26.78m | -- | -- | 6.28 | -- | -- | -0.1977 | -0.1977 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -195.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
| Equillium Inc | 42.62m | -8.32m | 27.01m | 45.00 | -- | 1.20 | -- | 0.6337 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 219.77k | 4.11% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 89.27k | 1.67% |
| UBS Securities LLCas of 30 Jun 2024 | 56.22k | 1.05% |
| Geode Capital Management LLCas of 30 Jun 2024 | 53.18k | 0.99% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 25.70k | 0.48% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 25.00k | 0.47% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 18.63k | 0.35% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 18.02k | 0.34% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 13.16k | 0.25% |
| Two Sigma Advisers LPas of 30 Jun 2024 | 12.82k | 0.24% |
